top of page
Search

Survey: Patients With Inflammatory Bowel Disease Report Better Quality of Life and Reduced Opioid Use With Cannabis


A University of Florida survey of 108 patients with inflammatory bowel disease found that nearly 88 percent reported improved quality of life with cannabis use, while roughly 59 percent said it reduced their opioid consumption.


Patients living with inflammatory bowel disease say cannabis may help them maintain independence, improve their quality of life and reduce their reliance on opioids, according to newly published survey data highlighted by National NORML.

The findings come from researchers affiliated with the University of Florida in Gainesville and were published in the peer-reviewed journal Medical Cannabis and Cannabinoids. The research adds to a growing body of evidence showing that many patients with Crohn’s disease and ulcerative colitis use cannabis to manage difficult symptoms and believe it improves their daily lives.

At the same time, the study was a survey—not a randomized clinical trial—and its results should not be interpreted as proof that cannabis treats the inflammation responsible for IBD or changes the course of the disease.


What Did the University of Florida Survey Find?

Researchers administered an anonymous, 39-question survey to 108 adults recruited through the University of Florida IBD clinic. Participants had been diagnosed with Crohn’s disease or ulcerative colitis and had a history of cannabis use.

The most notable findings included:

  • 87.6 percent reported that cannabis improved their quality of life.

  • 61.3 percent said cannabis improved their ability to live independently.

  • 59.3 percent believed cannabis use had reduced their opioid consumption.

  • Patients with a history of bowel surgery were more likely to report using cannabis for more than five years and using it at least weekly.

The researchers also found that depression or anxiety was common among respondents, reported by 61.1 percent of participants. Among cannabis users with a history of IBD-related hospitalization, the odds of reporting depression or anxiety and diarrhea symptoms were higher.

These results provide a window into why some people with IBD turn to cannabis: not necessarily as a cure, but as a tool they believe helps them manage symptoms and function more fully in everyday life.


What Is Inflammatory Bowel Disease?

Inflammatory bowel disease, or IBD, is an umbrella term that primarily includes Crohn’s disease and ulcerative colitis. Both are chronic conditions involving inflammation of the gastrointestinal tract, but they affect the digestive system differently.

Crohn’s disease can affect any portion of the gastrointestinal tract and may involve multiple layers of the bowel wall. Ulcerative colitis affects the colon and rectum, primarily involving the innermost lining.

Symptoms can include abdominal pain, diarrhea, fatigue, appetite loss, nausea, weight loss and rectal bleeding. The severity and pattern of symptoms can vary substantially from one patient to another, and the conditions can interfere with work, sleep, travel and social activities.


Why the Reported Reduction in Opioid Use Matters

Pain can be a significant part of living with IBD, particularly during severe symptoms, complications or recovery from surgery. But long-term opioid use carries serious risks, including tolerance, physical dependence, overdose and, in some patients, worsening gastrointestinal problems.

That makes the survey’s opioid-related finding especially noteworthy. Nearly six in ten respondents said cannabis had reduced their opioid consumption.

This does not establish that cannabis caused the reduction, nor does it mean patients should stop prescribed medication without medical supervision. It does, however, reinforce the need for researchers and clinicians to examine cannabis more closely as a possible component of symptom-management and harm-reduction strategies.


Symptom Relief Is Not the Same as Treating IBD Inflammation

The distinction between feeling better and controlling the underlying disease is essential.

Patients may experience relief from pain, nausea, poor appetite, sleep disruption or anxiety while intestinal inflammation continues. Existing reviews have generally found that cannabis and cannabinoids may improve certain symptoms and quality-of-life measures, but evidence that they induce remission or reliably reduce objective inflammation remains limited.

For that reason, cannabis should not be viewed as a substitute for medications prescribed to control Crohn’s disease or ulcerative colitis. Patients who use cannabis should continue appropriate monitoring and discuss symptoms, medications and cannabis use openly with a qualified healthcare professional.


What Are the Study’s Limitations?

The findings are important, but several limitations should shape how they are understood:

  • The study relied on participants’ own recollections and perceptions.

  • It included only 108 respondents from a single university clinic.

  • There was no placebo or non-cannabis comparison group.

  • Cannabis products, doses, cannabinoid profiles and methods of administration can vary widely.

  • The survey cannot prove that cannabis caused the reported improvements or opioid reductions.

Those limitations do not invalidate the patients’ experiences. Rather, they show why larger controlled studies are needed to determine which cannabinoids, formulations and dosing strategies may offer benefits—and which patients face the greatest risks.


What the Researchers Said

The authors described people with IBD as a distinct patient population that sometimes relies on cannabis to manage debilitating symptoms. They said the study can help close gaps in knowledge and support more evidence-based conversations between patients and physicians as medical cannabis access expands.

That goal is particularly relevant because patients are already using cannabis, whether or not medical education and clinical research have caught up. Honest communication allows clinicians to consider possible drug interactions, impairment, mental-health risks, product consistency and the danger of masking symptoms that require medical attention.


What This Means for Florida Patients

Florida recognizes Crohn’s disease as a qualifying condition for medical marijuana. Other patients may qualify when a physician determines that they have a medical condition of the same kind or class as a listed condition, subject to state law and the physician’s professional judgment.

Access alone, however, is not a substitute for good information. Patients deserve product transparency, evidence-based education and the freedom to speak with their doctors without stigma. They also deserve research policies that allow scientists to investigate cannabis with the rigor expected of any other potential therapeutic option.

For advocates, the study is another reminder that cannabis policy is a healthcare issue as well as a criminal-justice issue. When patients report meaningful improvements in quality of life and reduced reliance on opioids, those experiences warrant serious scientific attention—not dismissal.


The Bottom Line

The University of Florida survey found that a large majority of participating IBD patients believed cannabis improved their quality of life. Many also reported greater independence and lower opioid consumption.

The findings are promising, but they remain patient-reported observations. Cannabis may help some people manage symptoms associated with Crohn’s disease or ulcerative colitis, yet current evidence does not establish it as a treatment for the underlying inflammation or a replacement for standard IBD care.

More rigorous research is needed. In the meantime, patients and healthcare providers should be able to discuss cannabis candidly, evaluate possible benefits and risks, and make decisions grounded in evidence rather than stigma.

This article is for educational and informational purposes only and is not medical advice. Patients should consult a qualified healthcare professional before changing any medication or treatment plan.


Frequently Asked Questions

Can cannabis cure inflammatory bowel disease?

No. Current evidence does not show that cannabis cures Crohn’s disease or ulcerative colitis. Some patients report symptom relief and improved quality of life, but that is different from controlling intestinal inflammation or changing the course of the disease.

What IBD symptoms may improve with cannabis?

Previous patient surveys and observational research have reported perceived relief involving abdominal pain, nausea, appetite, sleep, stress and other symptoms. Responses vary, and more controlled research is needed.

Did cannabis reduce opioid use in this study?

About 59 percent of respondents believed cannabis had reduced their opioid consumption. Because the study was observational and based on self-reporting, it cannot prove that cannabis directly caused the reduction.

Should a patient stop taking IBD medication if cannabis helps symptoms?

No patient should stop or change prescribed medication without consulting their healthcare provider. Symptom improvement does not necessarily mean that underlying inflammation is controlled.

Where did this research come from?

The survey was conducted by researchers affiliated with the University of Florida and published in Medical Cannabis and Cannabinoids. This report is based on the original National NORML news article and the peer-reviewed study.


Sources


 
 
 

Comments

bottom of page